Acumen Q1 2022 net loss $9.1M; cash $216.7M, runway through 2025

Acumen Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.23

Cash, cash equivalents and marketable securities totaled $216.7M as of March 31, 2022, down from $225.9M at year-end 2021; expected to fund operations through 2025.
R&D expenses rose to $6.0M from $2.6M YoY due to ongoing Phase 1 trial (INTERCEPT-AD) of ACU193 for early Alzheimer's.
Net loss was $9.1M vs $27.0M in Q1 2021; prior-year loss included $23.2M non-cash expense from warrant/liability fair value changes.
Topline data from INTERCEPT-AD Phase 1 trial expected in first half of 2023; enrollment ongoing.
Preclinical evidence supporting ACU193's selective targeting of soluble amyloid-beta oligomers published in Frontiers in Neuroscience.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.